Cardinal Health Reports Strong Q3 2026 Earnings with Raised Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CAH?
Source: seekingalpha
- Significant Revenue Growth: Cardinal Health's total revenue increased by 11% to $61 billion in Q3, primarily driven by strong performance in its Pharmaceutical and Specialty Solutions business, demonstrating the company's competitive edge and sustained growth potential in the market.
- Improved Profitability: Enterprise operating earnings rose by 18% to $956 million, reflecting the company's successful positioning in higher-margin businesses, which also provides funding for future investments and expansions.
- Optimistic Outlook: Management raised the fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80 and adjusted free cash flow guidance to a range of $3.3 billion to $3.7 billion, indicating strong confidence in future performance and proactive market strategies.
- Strong Specialty Business Growth: The Specialty segment saw over 20% revenue growth in Q3, with expectations for Specialty revenue to exceed $50 billion in fiscal 2026, highlighting the company's advantageous position in rapidly growing niche markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 202.820
Low
209.00
Averages
225.18
High
244.00
Current: 202.820
Low
209.00
Averages
225.18
High
244.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardinal Health Reports Mixed Quarterly Results, Shares Decline
- Quarterly Revenue Growth: Cardinal Health reported an 11% year-over-year revenue increase to $60.94 billion for the quarter ending March 31, although it fell short of the $61.7 billion expectation, indicating the impact of market demand fluctuations on performance.
- Adjusted Earnings Per Share: The company posted adjusted EPS of $3.17, surpassing the consensus estimate of $2.79, demonstrating strong profitability despite overall sales missing expectations across all segments.
- Free Cash Flow Performance: Free cash flow reached $3.3 billion, three times the Street's consensus estimate, showcasing the company's robust cash management capabilities, although challenges persist in the Global Medical Products and Distribution segment.
- Full-Year Earnings Outlook Raised: Cardinal raised its adjusted earnings outlook for fiscal year 2026 to $10.70 to $10.80 per share, ahead of the Street estimate of $10.31, although only 13 cents of the increase is attributed to operational performance, reflecting cautious market sentiment regarding future growth.
See More
Cardinal Health Reports Strong Q3 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cardinal Health's total revenue increased by 11% to $61 billion in Q3, primarily driven by strong performance in its Pharmaceutical and Specialty Solutions business, demonstrating the company's competitive edge and sustained growth potential in the market.
- Improved Profitability: Enterprise operating earnings rose by 18% to $956 million, reflecting the company's successful positioning in higher-margin businesses, which also provides funding for future investments and expansions.
- Optimistic Outlook: Management raised the fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80 and adjusted free cash flow guidance to a range of $3.3 billion to $3.7 billion, indicating strong confidence in future performance and proactive market strategies.
- Strong Specialty Business Growth: The Specialty segment saw over 20% revenue growth in Q3, with expectations for Specialty revenue to exceed $50 billion in fiscal 2026, highlighting the company's advantageous position in rapidly growing niche markets.
See More
Strong Earnings Reports from Top Tech Giants
- Alphabet's Strong Performance: Alphabet's earnings report exceeded expectations with strong performance in search, subscriptions, and cloud services, leading to an 8% stock increase and reflecting significant returns on AI investments, boosting market confidence.
- Amazon's AWS Growth: AWS growth accelerated to 28%, with strong performance in advertising and e-commerce, resulting in a stock increase of over 3.5%, while maintaining a full-year capital expenditure of $200 billion, indicating confidence in future growth.
- Microsoft's Cloud Stability: Microsoft reported a 40% growth in cloud services, and despite a stock drop of over 1%, analysts raised price targets, suggesting optimism about its long-term prospects, alongside an increase in capital expenditures.
- Meta's Stock Decline: Meta Platforms saw its stock drop over 8.5% due to an increased capital expenditure forecast, despite solid quarterly results; however, a 5% decline in daily active users raised concerns about its growth outlook.
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
Cardinal Health Q3 Earnings Beat Expectations
- Earnings Performance: Cardinal Health reported a Q3 non-GAAP EPS of $3.17, exceeding expectations by $0.38, which underscores the company's robust profitability and boosts market confidence in its future performance.
- Revenue Growth Miss: Despite a 10.9% year-over-year revenue increase to $60.9 billion, the figure fell short of expectations by $1.34 billion, indicating potential challenges from increased market competition and cost pressures affecting sales performance.
- Debt Management and Buyback: The company completed an additional $250 million share repurchase, bringing the total for FY26 to $1 billion, demonstrating proactive measures in optimizing capital structure and enhancing shareholder value.
- Guidance Upgrade: Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80, reflecting a growth rate of 30% to 31%, driven by strong performance in its Pharmaceutical and Specialty Solutions segments, which enhances investor confidence in the company's future growth prospects.
See More
Cardinal Health Reports Decline in Q3 Earnings
- Earnings Decline: Cardinal Health reported third-quarter earnings of $399 million, or $1.69 per share, which represents a significant drop from last year's $506 million and $2.10 per share, indicating pressure on profitability.
- Adjusted Earnings: Excluding items, the adjusted earnings stood at $750 million, or $3.17 per share, reflecting relative stability in core operations despite the overall earnings decline.
- Revenue Growth: The company experienced an 11% year-over-year revenue increase, reaching $60.940 billion compared to $54.878 billion last year, suggesting strong market demand that may support future profitability recovery.
- Full-Year Guidance: Cardinal Health provided full-year EPS guidance of $10.70 to $10.80, indicating that despite the current quarter's poor performance, the management remains cautiously optimistic about future earnings prospects, demonstrating confidence in the business outlook.
See More
Cardinal Health Reports Mixed Quarterly Results, Shares Decline
- Quarterly Revenue Growth: Cardinal Health reported an 11% year-over-year revenue increase to $60.94 billion for the quarter ending March 31, although it fell short of the $61.7 billion expectation, indicating the impact of market demand fluctuations on performance.
- Adjusted Earnings Per Share: The company posted adjusted EPS of $3.17, surpassing the consensus estimate of $2.79, demonstrating strong profitability despite overall sales missing expectations across all segments.
- Free Cash Flow Performance: Free cash flow reached $3.3 billion, three times the Street's consensus estimate, showcasing the company's robust cash management capabilities, although challenges persist in the Global Medical Products and Distribution segment.
- Full-Year Earnings Outlook Raised: Cardinal raised its adjusted earnings outlook for fiscal year 2026 to $10.70 to $10.80 per share, ahead of the Street estimate of $10.31, although only 13 cents of the increase is attributed to operational performance, reflecting cautious market sentiment regarding future growth.
See More
Cardinal Health Reports Strong Q3 2026 Earnings with Raised Guidance
- Significant Revenue Growth: Cardinal Health's total revenue increased by 11% to $61 billion in Q3, primarily driven by strong performance in its Pharmaceutical and Specialty Solutions business, demonstrating the company's competitive edge and sustained growth potential in the market.
- Improved Profitability: Enterprise operating earnings rose by 18% to $956 million, reflecting the company's successful positioning in higher-margin businesses, which also provides funding for future investments and expansions.
- Optimistic Outlook: Management raised the fiscal 2026 non-GAAP EPS guidance to $10.70 to $10.80 and adjusted free cash flow guidance to a range of $3.3 billion to $3.7 billion, indicating strong confidence in future performance and proactive market strategies.
- Strong Specialty Business Growth: The Specialty segment saw over 20% revenue growth in Q3, with expectations for Specialty revenue to exceed $50 billion in fiscal 2026, highlighting the company's advantageous position in rapidly growing niche markets.
See More
Strong Earnings Reports from Top Tech Giants
- Alphabet's Strong Performance: Alphabet's earnings report exceeded expectations with strong performance in search, subscriptions, and cloud services, leading to an 8% stock increase and reflecting significant returns on AI investments, boosting market confidence.
- Amazon's AWS Growth: AWS growth accelerated to 28%, with strong performance in advertising and e-commerce, resulting in a stock increase of over 3.5%, while maintaining a full-year capital expenditure of $200 billion, indicating confidence in future growth.
- Microsoft's Cloud Stability: Microsoft reported a 40% growth in cloud services, and despite a stock drop of over 1%, analysts raised price targets, suggesting optimism about its long-term prospects, alongside an increase in capital expenditures.
- Meta's Stock Decline: Meta Platforms saw its stock drop over 8.5% due to an increased capital expenditure forecast, despite solid quarterly results; however, a 5% decline in daily active users raised concerns about its growth outlook.
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
Cardinal Health Q3 Earnings Beat Expectations
- Earnings Performance: Cardinal Health reported a Q3 non-GAAP EPS of $3.17, exceeding expectations by $0.38, which underscores the company's robust profitability and boosts market confidence in its future performance.
- Revenue Growth Miss: Despite a 10.9% year-over-year revenue increase to $60.9 billion, the figure fell short of expectations by $1.34 billion, indicating potential challenges from increased market competition and cost pressures affecting sales performance.
- Debt Management and Buyback: The company completed an additional $250 million share repurchase, bringing the total for FY26 to $1 billion, demonstrating proactive measures in optimizing capital structure and enhancing shareholder value.
- Guidance Upgrade: Cardinal Health raised its fiscal year 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80, reflecting a growth rate of 30% to 31%, driven by strong performance in its Pharmaceutical and Specialty Solutions segments, which enhances investor confidence in the company's future growth prospects.
See More
Cardinal Health Reports Decline in Q3 Earnings
- Earnings Decline: Cardinal Health reported third-quarter earnings of $399 million, or $1.69 per share, which represents a significant drop from last year's $506 million and $2.10 per share, indicating pressure on profitability.
- Adjusted Earnings: Excluding items, the adjusted earnings stood at $750 million, or $3.17 per share, reflecting relative stability in core operations despite the overall earnings decline.
- Revenue Growth: The company experienced an 11% year-over-year revenue increase, reaching $60.940 billion compared to $54.878 billion last year, suggesting strong market demand that may support future profitability recovery.
- Full-Year Guidance: Cardinal Health provided full-year EPS guidance of $10.70 to $10.80, indicating that despite the current quarter's poor performance, the management remains cautiously optimistic about future earnings prospects, demonstrating confidence in the business outlook.
See More
